REVEAL GENOMICS®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical impact of HER2DX®, its genomic diagnostic test designed for early-stage HER2-positive (HER2+) breast cancer. The study, now published in ESMO Real World Data and Digital Oncology, is the first prospective real-world investigation assessing the impact of HER2DX® results on treatment decision-making in ...